Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes

Ting Zhou,Ping Yang,Sanyuan Tang,Zhongshan Zhu,Xiaobing Li,Zhou Yang,Ruoxia Wu,Xuefei Tian,Liang Li
DOI: https://doi.org/10.1155/2021/5512325
IF: 4.501
2021-07-27
Journal of Oncology
Abstract:Aims. Lung adenocarcinoma (LUAD) cells could escape from the monitoring of immune cells and metastasize rapidly through immune escape. Therefore, we aimed to develop a method to predict the prognosis of LUAD patients based on immune checkpoints and their associated genes, thus providing guidance for LUAD treatment. Methods. Gene sequencing data were downloaded from the Cancer Genome Atlas (TCGA) and analyzed by R software and R Bioconductor software package. Based on immune checkpoint genes, kmdist clustering in ConsensusClusterPlus R software package was utilized to classify LUAD. CIBERSORT was used to quantify the abundance of immune cells in LUAD samples. LM22 signature was performed to distinguish 22 phenotypes of human infiltrating immune cells. Gene set variation analysis (GSVA) was performed on immune checkpoint cluster and immune checkpoint score using GSVA R software package. The risk score was calculated by LASSO regression coefficient. Gene Ontology (GO), Hallmark, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed. PROC was performed to generate the ROC curve and calculate the area under the curve (AUC). Results. According to the immune checkpoint, LUAD was classified into clusters 1 and 2. Survival rate, immune infiltration patterns, TMB, and immune score were significantly different between the two clusters. Functional prediction showed that the functions of cluster 1 focused on apoptosis, JAK/STAT signaling pathway, TNF-α/NFκB signaling pathway, and STAT5 signaling pathway. The risk score model was constructed based on nine genes associated with immune checkpoints. Survival analysis and ROC analysis showed that patients with high-risk score had poor prognosis. The risk score was significantly correlated with cancer status (with tumor), male proportion, status, tobacco intake, and cancer stage. With the increase of the risk score, the enrichment of 22 biological functions increased, such as p53 signaling pathway. The signature was verified in IMvigor immunotherapy dataset with excellent diagnostic accuracy. Conclusion. We established a nine-gene signature based on immune checkpoints, which may contribute to the diagnosis, prognosis, and clinical treatment of LUAD.
oncology
What problem does this paper attempt to address?
### The Problem the Paper Attempts to Solve This paper aims to predict the prognosis of Lung Adenocarcinoma (LUAD) patients through immune checkpoints and their related genes, and to provide guidance for LUAD treatment. Specifically, the researchers hope to solve the problem through the following steps: 1. **Classify LUAD Patients**: Classify LUAD patients into different subgroups based on immune checkpoint genes. 2. **Analyze Clinical Characteristics**: Detect differences in clinical characteristics among classified patients, such as survival rate, immune infiltration patterns, tumor mutation burden (TMB), and immune scores. 3. **Establish a Risk Scoring Model**: Screen genes related to immune checkpoints and construct a risk scoring model to evaluate its predictive ability for patient prognosis. 4. **Validate the Model's Effectiveness**: Validate the diagnostic accuracy of the risk scoring model using internal and external datasets. ### Background Lung Adenocarcinoma (LUAD) accounts for 40% of lung cancer patients and is one of the main subtypes of lung cancer. LUAD is characterized by diffuse metastasis and poor prognosis, with a survival rate of less than 5 years. Due to the high resistance of LUAD to radiotherapy and chemotherapy, finding new treatment methods is particularly urgent. In recent years, immunotherapy has become a new strategy for cancer treatment. The immune system plays an important role in the growth and metastasis of cancer cells, but the complex tumor microenvironment is a significant reason for the failure of immunotherapy. Therefore, predicting the prognosis and treatment response of LUAD patients through immune checkpoints is of great significance. ### Methods 1. **Data Acquisition and Preprocessing**: Download RNA sequencing data from the TCGA database and convert it to TPM values. Download the GSE68465 dataset from the GEO database as an external validation set. 2. **Classification of Immune Checkpoint-Related Genes**: Use the kmdist clustering method to classify LUAD patients based on immune checkpoint genes. 3. **Estimation of Immune Cell Infiltration**: Use the CIBERSORT algorithm to quantify the abundance of immune cells in LUAD samples. 4. **Pathway Analysis**: Use the GSVA package for gene set variation analysis, including GO, Hallmark, and KEGG pathway analysis. 5. **Establishment of a Risk Scoring Model**: Screen differentially expressed genes related to immune checkpoints through univariate Cox regression analysis and random forest method, and finally determine the risk scoring model through the LASSO regression method. 6. **Survival Curve and ROC Analysis**: Generate survival curves using the Kaplan-Meier method and calculate the area under the ROC curve (AUC) using the pROC package. ### Results 1. **Clustering Results of Immune Checkpoint Genes**: LUAD patients were divided into 2 subgroups (Cluster 1 and Cluster 2), with significant differences in survival rate, immune infiltration patterns, TMB, and immune scores between the two subgroups. 2. **Functional Analysis**: GO, Hallmark, and KEGG pathway analysis showed that the genes in Cluster 1 were mainly enriched in apoptosis, JAK/STAT signaling pathway, TNF-α/NFκB signaling pathway, and STAT5 signaling pathway. 3. **Establishment of a Risk Scoring Model**: 9 genes related to immune checkpoints were screened, and a risk scoring model was established. Survival analysis and ROC analysis indicated that patients with high-risk scores had poor prognosis. 4. **Model Validation**: The diagnostic accuracy of the risk scoring model was validated in the IMvigor immunotherapy dataset. ### Conclusion The researchers established a 9-gene risk scoring model based on immune checkpoints, which can be used for the diagnosis, prognosis evaluation, and clinical treatment of LUAD. This finding provides new ideas for precision medicine in LUAD.